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Graphical abstract 
We report herein the design and synthesis of a series of novel nitrobenzamide derivatives. Results reveal that A6, A11, C1 and C4 have not only the same excellent 
MIC values of <0.016 μg/mL against drug-resistant clinical isolates as lead 1, but also acceptable safety indices (SI>1500), opening a new direction for further 
development. 
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We report herein the design and synthesis of a series of novel nitrobenzamide 
derivatives. Results reveal that many of them display considerable in vitro 
antitubercular activity. Four N-benzyl or N-(pyridine-2-yl)methyl 3,5-
dinitrobenzamides A6, A11, C1 and C4 have not only the same excellent MIC values 
of <0.016 μg/mL against both drug-sensitive MTB strain H37Rv and two drug-
resistant clinical isolates as PBTZ169 and the lead 1, but also acceptable safety 
indices (SI>1500), opening a new direction for further development. Keywords: nitrobenzamides 
synthesis 
antimycobacterial activity 
tuberculosis 
    Tuberculosis (TB) has existed for millennia and remains a major global health problem [1]. It is a widespread 
infectious disease predominantly caused by Mycobacterium tuberculosis (MTB), which can be transmitted through 
the air as droplets and affects the lungs [2]. The World Health Organization (WHO) estimated that approximately 
10.4 million people were infected and 1.3 million died from TB worldwide in 2016 [1]. The spread of multidrug-
resistant TB (MDR-TB) and the emergence of extensively drug-resistant TB (XDR-TB) have reinvigorated drug 
discovery efforts in search of novel agents [3-6]. Despite the introduction of Bedaquiline [7] and Delamanid [8] to 
the repertoire of anti-TB therapies for MDR-TB, some adverse events have been noted [9]. Therefore, it is urgently 
needed to develop antimycobacterial molecules with new mechanisms of action and that are active against MDR- 
and XDR-TB [10]. 
    Decaprenyl phosphoryl-β-D-ribose 2′-epimerase (DprE1) was identified as a potential target for developing 
potent and safer anti-TB agents [11-13]. Some new chemical entities (NCEs) were found to have potent activity 
against MDR/XDR-MTB as covalent or noncovalent inhibitors of the DprE1 enzyme [14-22], such as nitroaromatic 
compounds DNB1, MTX and PBTZ 169 (Fig. S1 in Supporting information). As the most advanced scaffold among 
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these NCEs, nitrobenzothiazinones (BTZs) have garnered great interest recently, and many series of BTZ derivatives 
were reported [23-26]. Above all, candidate PBTZ169 entered in Phase II clinical trials in 2017 [1]. 
    In our previous studies, many BTZs containing various cyclic ketoximes, spiro-heterocycles and piperidines 
moieties were found to have considerable antitubercular activity [27-29]. Recently, N-(4-(4-
trifluoromethyl)piperidin-1-yl)benzyl nitrobenzamides 1 and 2 (Fig. 1) were identified as new anti-TB agents by the 
thiazinone ring opening of PBTZ169 in our lab [30]. Both of them with simpler structures than PBTZ169, show 
potent activity against MTB H37Rv strain (MIC ≤ 0.016 μg/mL). Moreover, compound 1 also displays acceptable 
safety and better PK properties than PBTZ169. 
     Inspired by the above research results, compounds 1 and 2 were employed as lead compounds, and the three 
moieties (A, B and C ring) were all explored in this study. We started with the modification of A ring and B ring. 
Replacement of X group on ring A with various substituents (Y) leaded to 3-nitrobenzamides bearing N-benzyl (A1-
4); introduction of pyridine as A ring while reserving the nitro group gave 5-nitronicotinamides A5. Subsequently, 
the B ring was changed to pyrin-3-yl or pyrin-2-yl leading to compounds B1-5 or C1-3 (Fig. 1). After identifying the 
optimal A and B rings, C ring was then further investigated. Our primary objective was to find optimized 
benzamides with potent antimycobacterial activity. A preliminary structure-activity relationship (SAR) study was 
also explored to facilitate the further development of these compounds. 
    Detailed synthetic pathways to side chains 68, leads 1, 2 and targets AC are shown in Schemes S1 and S2 
(Supporting information), respectively. Commercially unavailable benzylamines and pyridinylmethylamines 68 
were first prepared according to Scheme S1. 4-Fluorobenzonitrile 3, 6-fluoronicotinonitrile 4 and 5-
fluoropicolinonitrile 5 were treated with various nitrogen heterocyclic amines ZH in DMSO in the presence of K2CO3 
at 80 oC, and the resulting condensates were subsequently reduced with LiAlH4 in THF to produce the desired 
compounds 6, 7 and 8, respectively. 
    Leads 1, 2 and targets A1-11, B1-21, C1-4 were easily obtained by coupling 3-nitrobenzoic acids 913 and 5-
nitronicotinic acid 14 with the above side chain compounds 68 or commercially available benzylamines 15ad in 
the presence of triethylamine and condensation agent bis(2-oxo-3-oxazolidinyl) phosphonic chloride (BOP-Cl) 
(Scheme S2).  
Table 1 
Structures and activity of compounds AC against MTB H37Rv. 
 
Compd. Y MIC (μg/mL) Compd. Y MIC (μg/mL) 
1 5-NO2 <0.016 B3 4,6-di-Cl >16 
2 5-CF3 0.016 B4 H 15.354 
A1 5-F 1.357 B5  15.176 
A2 5-Br 0.459 C1 5-NO2 <0.016 
A3 4,6-di-Cl >16 C2 H 31.088 
A4 H >16 C3  15.732 
A5  14.735 PBTZ169  <0.016 
B1 5-NO2 0.059 INH  0.0781 
B2 5-Br 0.944 RFP  0.0781 
INH: isoniazid; RFP: rifampicin. 
   The target compounds A15, B15 and C13 bearing different kinds of substituents to ensure A and B rings 
flexibility and structure diversity, were first synthesized. They were preliminarily screened for in vitro activity 
against MTB H37Rv ATCC27294 strain, using the Microplate Alamar Blue Assay (MABA) [31,32]. The minimum 
inhibitory concentration (MIC) is defined as the lowest concentration effecting a reduction in fluorescence of >90% 
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relative to the mean of replicate bacterium-only controls. The MIC values of the compounds along with the leads 1 
and 2, PBTZ169, isoniazid (INH), and rifampicin (RFP) for comparison were obtained from three independent 
experiments and presented in μg/mL in Table 1. 
Effect of the substituents on A ring was first investigated. The nature and position of the substituents greatly 
influence activity. Replacement of one nitro group of 1 or the trifluoromethyl of 2 with halogen in compounds A1
（F）and A2 (Br) leads to decreased activity (MIC: 1.357 and 0.459 μg/mL, respectively). Introduction of 4,6-
dichloro (A3) or reservation of one nitro (A4) destroys activity. Moreover, N-benzyl nicotinamide analogue (A5) 
displays very poor potency. Overall, these results reveal that the presence of a strong electron-withdrawing group 
(CF3, NO2) at C-5 position of nitrobenzamide core is essential for excellent activity (Table 1). 
 
Table 2 
Structures and activity of 3,5-dinitrobenzamides AC against MTB H37Rv. 
 
Compd. Z MIC (μg/mL) Compd. Z MIC (μg/mL) 
A6 
 
<0.016 B12 
 
 
 
0.452 
A7 
 
0.060 B13 
 
0.235 
A8 F 0.120 B14 
 
0.480 
A9 CF3 0.059 B15 
 
1.255 
A10 OCF3 0.033 B16 
 
0.210 
A11 OCH3 <0.016 B17 
 
0.178 
B6 
 
0.094 B18 
 
0.233 
B7 
 
0.030 B19 
 
0.491 
B8 
 
0.030 B20 
 
0.973 
B9 
 
0.108 B21 
 
0.143 
B10 
 
0.059 C4 
 
<0.016 
B11 
 
0.119 PBTZ169  <0.016 
 
     In further modifications, the benzene ring (B ring) was replaced by a pyridine ring. As shown in Table 1, in 
accordance with SAR of N-benzyl analogues (A15), N-(pyridin-3-yl)methyl and N-(pyridin-2-yl)methyl 3,5-
dinitrobenzamides (B1, C1) demonstrate potent MIC values of 0.059 and <0.016 μg/mL against this strain, 
respectively, indicating that N-pyridinylmethyl on the amide is also acceptable. 
    Based on the above SAR, and better activity of lead compound 1 than 2, N-benzyl and N-pyridinylmethyl 3,5-
dinitrobenzamides with various groups at para-position of B ring were further designed and synthesized. As shown 
in Table 2, all of them show good to excellent activity against MTB H37Rv strain (MIC: <0.016–0.973 μg/mL), with 
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one exception B15. Among them, nine compounds A6, 7, 911, B7, 8, 10 and C4 (MIC: <0.0160.060 μg/mL) are 
more active than INH/RFP (MIC: 0.0781 μg/mL), and roughly comparable to PBTZ169.  
 
aMDR-TB 16833 and MDR-TB 16995 were isolated from patients in Beijing Chest Hospital; bthe 50% cytotoxic concentration; cSI: selectivity index for MTB 
H37Rv, CC50 / MIC 
 
    For N-benzyl 3,5-dinitrobenzamides, the presence of a halogen atom instead of trifluoromethyl at para-position 
of the piperidine ring (C ring) was found to be also favorable. For example, compound A6 shows the same MIC 
value of <0.016 μg/mL as the lead 1. Introduction of an additional aromatic moiety on C ring, such as 4-
fluorophenyl (A7, MIC: 0.059 μg/mL), is also acceptable. More interestingly, removal of C ring and direct 
attachment of a simple group to B ring remain considerable activity (A811), and an electron-donating group 
(OCH3) is preferred over an electron-withdrawing one (CF3, OCF3) or a halogen atom (F). 
    For N-(pyridin-3-yl)methyl 3,5-dinitrobenzamides, the presence of a halogen atom (Cl, Br) instead of 
trifluoromethyl on C ring is more beneficial to activity (B1 vs. B7 and B8), and replacement of C ring in B1 with 
thiomorpholine in compound B10 maintains the same potent activity (MIC: 0.059 μg/mL). However, introduction of 
4-substituented phenyls on C ring, or replacement of the piperidine with piperazines bearing a substituted phenyl 
moiety leads decreased activity (B1 vs B1121). Conversely, N-(pyridin-2-yl)methyl compound C4 with a 4-
(fluorophenyl)piperazine as C ring, displays the same potent MIC value of <0.016 μg/mL as C1, much more active 
than the corresponding N-(pyridin-3-yl)methyl analogue B16 (MIC: 0.210 μg/mL) (Table 2). 
     Encouraged by their strong potency against the drug sensitive MTB H37Rv strain (MIC: <0.0160.060 μg/mL), 
eleven 3,5-dinitrobenzamide derivatives A6, 7, 911, B1, 7, 8, 10 and C1, 4 were further evaluated against two 
clinical isolated MTB-MDR (16833 and 16995) strains resistant to both INH and RFP. The cytotoxic potential of 
these compounds was also investigated in a mammalian Vero cell line by MTS assay. As shown in Table 3, all of 
them exhibit potent MIC values of <0.0160.071 μg/mL, similar to that against MTB H37Rv. Among of them, 
compounds A6, A11, C1 and C4 have the same excellent activity (MIC: <0.016 μg/mL) as PBTZ169 and the lead 1. 
With a few exceptions, these compounds (CC50: 22.63–34.57 μg/mL) are less cytotoxic than the lead 1, although 
generally more cytotoxic than PBTZ169. 
     Lipinski’s rules are important guidelines for determining drug-likeness compounds [33]. The related values of 
most potent compounds A6, A11, C1 and C4 were calculated using the online chemo-informatics software 
molinspiration (http://www.molinspiration.com). As shown in Table S1 (Supporting information), none violation of 
Lipinski’s rule-of-five was found among compounds A6, A11, and C1. The hydrogen bond acceptors of compound 
C4 (HBA = 11) are more than the recommended number (HBA <10). However, compound C4 is still incorporate 
with the Lipinski’s rule-of-five (violations ≤1). Thus, these compounds display good drug like properties, are all 
deserved further development. 
     In conclusion, a series of nitrobenzamide derivatives containing N-benzyl or N-pyridinylmethyl moieties, based 
on lead compounds 1 and 2 discovered in our lab, were designed and synthesized as new anti-TB agents. Many of 
them exhibit potent in vitro antitubercular activity. Especially, N-benzyl 3,5-dinitrobenzamides A6 and A11, and N-
(pyridine-2-yl)methyl analogues C1 and C4 have not only the same excellent activity (MIC: <0.016 μg/mL) against 
both drug-sensitive MTB strain H37Rv and two drug-resistant clinical isolates as PBTZ169 and the lead 1, but also 
have acceptable safety indices (SI: >1500). In addition, compounds A6, A11, C1 and C4 display good drug like 
properties, suggesting these compounds may serve as new and promising candidates for further antitubercular 
drug discovery. By the way, the further expansion of the 3,5-dinitrobenzamides is underway to find potent anti-TB 
agents. 
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Fig. 1. Design of the new molecules. 
 
 
Table 3 
Activity against MDR-MTB, cytotoxicity and selectivity index (SI) values for selected compounds. 
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Compd. MIC (g/mL) CC50b 
(μg/mL) 
 
SIc 
MDR-MTB 
16833a 
MDR-MTB 
16995a 
1 <0.016 <0.016 20.15 >1259 
A6 <0.016 <0.016 24.74 >1546 
A7 0.071 0.056 10.51 175 
A9 0.070 0.042 33.62 569 
A10 0.029 0.056 31.21 945 
A11 <0.016 <0.016 28.02 >1751 
B1 0.043 0.028 16.80 284 
B7 0.030 0.056 23.17 772 
B8 0.030 0.029 22.63 754 
B10 0.063 0.060 17.60 298 
C1 <0.016 <0.016 26.61 >1663 
C4 <0.016 <0.016 34.57 >2160 
PBTZ169 <0.016 <0.016 36.68 >2292 
INH >40 >40 NT  
RFP >40 >40 NT  
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